发布时间：2008.8

摘要

Countries covered: Slovenia

Despite being smaller and more mature than most of its Central and Eastern European (CEE) peers,Slovenia is still regarded as a reasonably viable shorter-term prospect for pharmaceutical activities. InQ308, Slovenia is found in joint ninth place, alongside Romania, out of the 17 markets surveyed in theCEE region. The country’s ranking is negatively affected by its limited population number, negligiblepopulation growth and the country’s inadequate IP laws, as well as the low market growth forecasts. Onthe other hand, the expansive private insurance coverage and established trade regimes with WesternEurope allow for good placement of novel drugs onto the market, which will be the main driver of growthover the coming years.

However, the government continues to strive to contain pharmaceutical expenditure through theintroduction of limits on prescribing and the use of hospitals, among other measures. As part of thisprocess, generics - mostly of expensive branded variety - may suffer price reductions in the comingyears. In the meantime, the over-the-counter (OTC) segment will benefit from high consumer incomes,rising health consciousness and an interest in alternative medicines.

In terms of the pharmaceutical industry, difficult conditions in the home market will continue to pushdomestic players to expand abroad. To this end, in April 2008, Krka opened a new business centre inFormer Yugoslav Republic (FYR) of Macedonia’s capital, signifying its commitment to other regionalmarkets. In 2007, Krka’s sales in Macedonia reached EUR10mn in 2007, with the company being thecountry’s second-largest supplier of pharmaceuticals. Shortly prior to the opening of the centre, Krkarevealed that its Q108 group sales were 19% higher than in the same period of 2007, reachingEUR243.7mn, with exports accounting for over 90% of total sales. Slovenian sales, however, droppedslightly to EUR24.9mn, illustrating the difficulties faced at home.

In the meantime, the Slovenian medical devices market is relatively advanced in relation to its CEE peers.Further commercial opportunities are provided by the country’s wealth, healthcare system modernisationand rising patient demands. While imports have traditionally dominated the medical devices landscape,exports have recorded strong growth in recent years, with the main destinations being the territories of theformer Yugoslavia.

目录及图表

Executive Summary

Slovenia Pharmaceuticals And Healthcare Industry SWOT

Slovenia Political SWOT

Slovenia Economic SWOT

Slovenia Business Environment SWOT

Pharmaceutical Business Environment Ratings

Table: Central and Eastern Europe Business Environment Rating

Limits Of Potential Returns

Risks To Realisation Of Returns

Slovenia - Market Summary

Regulatory Regime

Intellectual Property Regime

IP Deficiencies

Patent Disputes

Pricing System

Reimbursement Policies

Eurozone Entry

Industry Developments

Health Status

Table: Leading Causes Of Death In Slovenia, 2002

Healthcare Sector

Healthcare Provision Developments

Healthcare Insurance

Healthcare Expenditure

Pharmaceutical Industry

Recent Industry Developments

Medical Devices

Industry Forecast Scenario

Overall Market Forecast

Table: Drug Expenditure And Prescription Market Indicators (EURmn unless otherwise stated)

Key Growth Factors - Industry

Table: Health Expenditure Indicators, 2006-2012

Macroeconomic Forecast Scenario

Table: Slovenia - Economic Activity

Patented Market Forecast

Table: Prescription Drug Market Indicators

Generics Markets Forecast

Table: Generic Market Indicators, 2006-2012

OTC Market Forecasts

Table: OTC Market Indicators (EURmn unless otherwise stated)

Export/Import Forecasts

Table: Table: Export/Import Indicators (US$mn unless otherwise stated)

Other Healthcare Data Forecasts

Table: Socio-Demographic Indicators

Key Risks To BMI’s Forecast Scenario

Competitive Landscape

Table: Leading Companies In Slovenia. 2007

Company Profiles

Multinational Company Profiles

GlaxoSmithKline

Sanofi-Aventis

Pfizer

Novartis

Merck & Co

Krka

Lek (Novartis/Sandoz)

BMI Forecast Modelling

How We Generate Our Pharmaceutical Industry Forecasts

Pharmaceutical Industry

Pharmaceutical Business Environment Ratings Methodology

Ratings Overview

Table: Pharmaceutical Business Environment Indicators

Weighting

Table: Weighting Of Components

Sources